News & Press Releases

PneumRx, a BTG International group company, is focused on developing minimally invasive solutions for unmet medical needs in pulmonary medicine. Please click on a link below to learn more about PneumRx and PneumRx Coils.

REVOLENS Randomized Clinical Trial

January 12, 2016

“We congratulate the investigators and the French Ministry of Health for completing this randomized clinical trial and for publishing the study results in one of the world’s top-ranked medical journals.” said Matthew Gantz, Executive VP, BTG International Inc., and President, PneumRx, Inc. “We are pleased to see a growing evidence base supporting the use of endobronchial coils to improve the lives of patients with severe emphysema and look forward to this becoming a standard of care option in France.”

To date, three (3) randomized, clinical trials of PneumRx’s coils have been completed: RESET (The Lancet Respiratory Medicine, 2013), REVOLENS (JAMA, 2016) and RENEW, the U.S. pivotal trial, which is expected to be published later in 2016.